Cambridge Healthtech Institute第1届

Bispecific Antibodies for Cancer Immunotherapy

( 对应癌症免疫疗法的双特异性抗体 )

对应癌症免疫疗法的次世代生物制剂的开发

2018年8月28日~29日

本单元以对应癌症免疫疗法的双特异性抗体为主题,以免疫确认点标的的双重抑制为目的之双特异性抗体的利用、T细胞重新导向双特异性生物制剂、T细胞的疲弊等相关临床前研究、转译研究与临床研究的成果将在此发表,此外强化效力及讲低毒性的策略、具备双特异性及多特异性的次世代生物制剂开发策略等内容也涵盖其中。

Cover will include, but is not limited to:

  • Reviving exhausted T-cells with dual costimulation
  • Engaging inhibitory and agonist receptors with bispecific biologics
  • Improving on-target efficacy and limiting off-target immunotoxicity
  • Preclinical and translational research for bispecific antibodies
  • T-cell-redirecting bispecific antibodies
  • Engineering bispecific and multi-specific platforms and constructs

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English





免费电子邮件通知服务